ARNAS Garibaldi Di Catania
- Address
- lock Available on a paid plan
Ophthalmology and Eye Disease Research at ARNAS Garibaldi Di Catania
The Department of Ophthalmology is actively studying a range of eye diseases, with a strong focus on thyroid eye disease and postoperative inflammation after cataract surgery. These trials are designed to improve symptom control, reduce inflammation, and evaluate new treatment options that may offer better outcomes for patients with vision-threatening conditions.
- Thyroid Eye Disease and related eye-symptom relief
- Post-cataract surgery inflammation and recovery
- Testing new therapies to improve comfort, safety, and eye health
Research at this site also reflects broader interest in analytical, diagnostic, and therapeutic techniques for ophthalmic care, supporting more precise and effective treatment strategies.
Oncology Research in Gastrointestinal Cancers
A major part of the clinical trial portfolio at ARNAS Garibaldi Di Catania focuses on neoplasms, especially cancers of the colon, rectum, stomach, and gastroesophageal junction. These studies are evaluating newer cancer treatments, combination strategies, and biomarker-guided approaches to improve survival and disease control.
- Metastatic colorectal cancer and locally advanced rectal cancer
- Gastric and gastroesophageal junction cancer
- Testing treatment effectiveness and personalized therapy choices
The research includes efforts to refine treatment for patients with advanced disease, including studies aimed at better response rates, longer survival, and improved matching of therapy to tumor biology.
Breast, Gynecologic, and Other Solid Tumor Studies
The site is also involved in trials for several other cancer types, including breast cancer, ovarian cancer, fallopian tube cancer, and peritoneal neoplasms. These studies are generally focused on improving outcomes after standard treatment, reducing recurrence risk, and testing targeted or immune-based therapies in difficult-to-treat cancers.
- High-risk HER2-positive breast cancer and triple negative breast cancer
- Ovarian, fallopian tube, and peritoneal cancers
- Evaluating new treatment options to delay relapse and improve disease-free survival
This area of research highlights a broad commitment to modern oncology, including studies that aim to make treatment more effective after surgery or initial therapy.
Hematology and Immune System Trials
Clinical research at the site includes hemic and lymphatic diseases as well as immune system diseases, with studies in mantle cell lymphoma, follicular lymphoma, chronic immune thrombocytopenia, and sickle cell disease. These trials are assessing new ways to improve blood counts, control disease activity, and support longer-term management.
- Lymphoma and relapsed or refractory blood cancers
- Chronic immune thrombocytopenia
- Testing therapies that may improve disease control and reduce complications
The research reflects an emphasis on both treatment effectiveness and safety in conditions where long-term disease management is especially important.
Cardiometabolic and Metabolic Disease Research
Another important area of activity involves cardiovascular diseases and nutritional and metabolic diseases, including atherosclerotic cardiovascular disease, type 2 diabetes, hypertension, overweight, obesity, and MASH/NASH. These studies are exploring prevention and treatment approaches that may lower long-term risk and improve overall health.
- Cardiovascular disease prevention and risk reduction
- Type 2 diabetes, hypertension, and weight management
- Evaluating therapies to improve metabolic control and reduce major complications
The cardiometabolic portfolio shows a strong interest in preventing serious events while also addressing common chronic conditions that affect quality of life.
Respiratory, Genetic, and Precision Medicine Studies
The research program also includes respiratory tract diseases and congenital, hereditary, and neonatal conditions, with trials in non-small cell lung cancer and mutation-defined cancers such as KRAS, HER2, and FGFR2b related disease. These studies are aimed at improving treatment selection and testing targeted therapies for patients with specific biological features.
- Advanced non-small cell lung cancer
- Biomarker-selected cancers such as KRAS- and HER2-driven disease
- Using precision medicine to match treatment with tumor characteristics
This work highlights the site’s interest in more personalized care, where treatment decisions are guided by tumor markers and disease biology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 79 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ARNAS Garibaldi Di Catania
lock Showing 1 of 49 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 79 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 7 | Unknown | 2019-08-26 | 2026-06-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.